Status:
TERMINATED
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Islet Cell
Carcinoma, Pancreas
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study randomized patients with advanced pancreatic islet cell tumors to receive either sunitinib or placebo. Patients who were randomized to sunitinib received 37.5 mg of sunitinib daily, those r...
Detailed Description
The study was terminated on 11 March 2009 because the independent Data Monitoring Committee determined that the study had met its primary endpoint in demonstrating improvement in progression-free surv...
Eligibility Criteria
Inclusion
- Well-differentiated advanced/metastatic pancreatic islet cell tumor
- Tumor has shown progression within the past year.
Exclusion
- Current treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational anticancer agent other than somatostatin analogues
- Prior treatment with any tyrosine kinase inhibitors or anti-VEGF\[Vascular endothelial growth factor\] angiogenic inhibitors.
- Prior treatment with non-VEGF-targeted angiogenic inhibitors is permitted
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
171 Patients enrolled
Trial Details
Trial ID
NCT00428597
Start Date
June 1 2007
End Date
April 1 2009
Last Update
October 11 2010
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Aurora, Colorado, United States, 80045
2
Pfizer Investigational Site
Iowa City, Iowa, United States, 52242
3
Pfizer Investigational Site
Worcester, Massachusetts, United States, 01605
4
Pfizer Investigational Site
Worcester, Massachusetts, United States, 01655